Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	217.79	269.57	519.27	1,323	286.93	291.14
Short-Term Investments	-	7.3	148.42	16.12	-	-
Cash & Short-Term Investments	217.79	276.87	667.69	1,339	286.93	291.14
Cash Growth	-46.04%	-58.53%	-50.15%	366.84%	-1.45%	5.02%
Accounts Receivable	189.89	140.74	58.53	81.32	320.84	169.03
Other Receivables	5.04	7.73	4.69	3.09	11.33	5.51
Receivables	194.92	148.47	63.22	84.41	332.17	174.54
Inventory	101.38	64.94	112.33	246.72	173.3	84.85
Prepaid Expenses	73.37	71.45	83.25	103.22	89.28	23.82
Other Current Assets	217.28	174.66	171.53	149.95	15.73	2.16
Total Current Assets	804.75	736.38	1,098	1,924	897.41	576.51
Property, Plant & Equipment	1,619	1,705	1,847	1,978	1,351	786.73
Long-Term Investments	157.45	177.87	190.81	199.51	109.59	191.81
Goodwill	23.92	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	9.28	12.34	18.98	25.93	33.71	36.72
Long-Term Deferred Tax Assets	100.86	98.6	95.49	89.72	81.11	83.45
Other Long-Term Assets	613.57	614.67	495.85	211.93	642.46	53.41
Total Assets	3,329	3,368	3,770	4,453	3,139	1,753
Accounts Payable	39.4	34.63	44.05	52.52	54.68	40.31
Accrued Expenses	90.25	98.05	112.32	104.21	96.4	66.6
Short-Term Debt	280	-	-	100	50	100
Current Portion of Long-Term Debt	196.55	168.08	125.92	105.88	15.6	-
Current Portion of Leases	37.59	31.92	30.57	37.28	28.59	24.33
Current Income Taxes Payable	0.01	-	-	-	-	0.65
Current Unearned Revenue	384.98	230.85	187.28	142.28	152.12	125.9
Other Current Liabilities	51.12	97.97	253.28	92.57	142.69	66.99
Total Current Liabilities	1,080	661.5	753.42	634.73	540.07	424.78
Long-Term Debt	482.81	611.37	530.4	656.32	474.4	-
Long-Term Leases	123.75	72.04	39.39	56.37	176.06	72.28
Long-Term Deferred Tax Liabilities	-	-	-	-	3.75	6.68
Other Long-Term Liabilities	-	-	-	-	38.07	37.14
Total Liabilities	1,686	1,345	1,323	1,347	1,232	540.89
Common Stock	2,072	2,070	2,059	2,053	1,533	1,282
Additional Paid-In Capital	62.66	421.11	1,074	1,468	576.95	53.11
Retained Earnings	-491.98	-466.91	-682.64	-406.83	-254.34	-207.23
Comprehensive Income & Other	-0.1	-0.79	-3.32	-8.8	50.72	83.41
Shareholders' Equity	1,643	2,023	2,447	3,106	1,907	1,212
Total Liabilities & Equity	3,329	3,368	3,770	4,453	3,139	1,753
Total Debt	1,121	883.39	726.28	955.85	744.64	196.61
Net Cash (Debt)	-902.91	-606.53	-58.59	383.63	-457.72	94.53
Net Cash Growth	-	-	-	-	-	-58.98%
Net Cash Per Share	-4.36	-2.94	-0.29	2.32	-3.08	0.73
Filing Date Shares Outstanding	207.2	207.01	205.89	205.31	153.33	128.24
Total Common Shares Outstanding	207.2	207.01	205.89	205.31	153.33	128.24
Working Capital	-275.15	74.89	344.59	1,289	357.34	151.73
Book Value Per Share	7.93	9.77	11.89	15.13	12.43	9.45
Tangible Book Value	1,609	1,987	2,404	3,056	1,849	1,151
Tangible Book Value Per Share	7.77	9.60	11.68	14.88	12.06	8.98
Buildings	792.86	792.86	792.86	791.68	-	-
Machinery	1,595	1,594	1,603	1,575	837.57	688.02
Construction In Progress	186.13	158.09	106.85	3.35	624.35	260.37
Leasehold Improvements	325.48	325.53	317.34	307.77	276.23	246.21

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.